Home > Resources > Whitepapers > Whitepaper: Phenotypic drug discovery with high content screening

Whitepaper: Phenotypic drug discovery with high content screening

January 25, 2018

Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.High Content Screening with detailed multiparametric assays in conjunction with powerful data visualisation and machine-learning tools provide a promising way to achieve this goal and turn phenotypic data into robust discoveries.

Spotlight

Canopy Biosciences

Canopy Biosciences®, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary platform ChipCytometry™ is an image-based high-plex proteomics instrument for spatial biology research that allows you to quantify virtually unlimited protein biomarkers on a sample with true single-cell resolution. We also offer services for gene expression profiling, including Illumina® RNA-Seq Assays, NanoString® GeoMx® Digital Spatial Profiling and nCounter® Assays. As a CLIA-certified laboratory, we provide support for preclinical and clinical trial studies with IHC, FISH and histopathology services. Founded in 2016, Canopy Biosciences® is headquartered in St. Louis, MO and has offices and laboratories in Hayward, CA as well as in Hannover and Leipzig, Germany.

OTHER WHITEPAPERS

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Synthetic Biology Biotechnology and AgTech

whitePaper | March 12, 2022

CRISPR, gene editing, biotech, precision agriculture and automation influencing the future of business, government, food, medicine, geopolitics and society

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

Risk assessment of fungal materials

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.